PA
CMTA

Perceptive Advisors’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

Perceptive Advisors’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,500,000
Closed -$17.6M – 129
2018
Q4 		$17.6M Buy
+1,500,000
New +$18.7M 0.67% 39
2017
Q4 		– Sell
-352,250
Closed -$6.29M – 169
2017
Q3 		$6.29M Buy
+352,250
New +$5.76M 0.24% 62

Other funds holding CMTA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KLCMU
Kite Lake Capital Management (UK) London, United Kingdom $125M AUM 198.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors's CMTA Position: Q1 2019 in Review

Perceptive Advisors sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q1 2019, closing a stake of 1,500,000 shares — an estimated $17.6M sold.

Perceptive Advisors first reported a position in CMTA in Q3 2017 and held it in 2 quarters. The position peaked at $17.6M in Q4 2018. 48 funds tracked by Wall St. Rank hold CMTA as of Q1 2019.

  • Perceptive Advisors reported no remaining Clementia Pharmaceuticals Inc. position as of Q1 2019 after selling out during the quarter.
  • Perceptive Advisors sold 1,500,000 Clementia Pharmaceuticals Inc. shares in Q1 2019, an estimated $17.6M.
  • Perceptive Advisors first reported a position in Clementia Pharmaceuticals Inc. in Q3 2017 and held it in 2 quarters.
  • Perceptive Advisors's Clementia Pharmaceuticals Inc. position peaked at $17.6M in Q4 2018.
  • 48 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q1 2019.

Based on Perceptive Advisors's 13F filing for Q1 2019, filed 15 May 2019.